Clinical Trials
34 trialsSorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Memorial Sloan Kettering Cancer Center
PIPAC in Gastric Peritoneal Metastasis
Chinese University of Hong Kong
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
Guangdong Provincial People's Hospital
Using Tumor Models to Determine Treatments
University Health Network, Toronto
TATE
Teclison Ltd.
EPICURE
Odense University Hospital
SBRTvsTACE
Lahey Clinic
SPECTRA
Imperial College London
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Eastern Cooperative Oncology Group
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery
Northwestern University
ABLATE
Imunon
PIPAC-GA01
Ruhr University of Bochum
Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
University Health Network, Toronto
HepSTAR
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
HCC
University of Pittsburgh
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
Centro Nacional de Investigaciones Oncologicas CARLOS III
Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
National Cancer Institute (NCI)
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Bayer
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
National Cancer Institute (NCI)
Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma
National Cancer Institute (NCI)
SoraDox
Martin-Luther-Universität Halle-Wittenberg
Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer
National Cancer Institute (NCI)
Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient
Chang Gung Memorial Hospital
Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
START
Taipei Veterans General Hospital, Taiwan
Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus
Dana-Farber Cancer Institute
Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer
National Center for Research Resources (NCRR)